Faulding receives FDA approval for generic anticonvulsant drug.

ELIZABETH, N.J.--(BUSINESS WIRE)--Nov. 1, 1996--

Seeks share of $264 million market

Faulding Inc.'s wholly owned subsidiary, Purepac Pharmaceutical Co., has received approval from the Food and Drug Administration to market clonazepam tablets, it was announced today by Richard F. Moldin, president and chief executive officer of Faulding Inc.

Clonazepam is an anticonvulsant used alone or as an adjunct in the treatment of the Lennox-Gastaut Syndrome (petit mal variant) akinetic and myoclonic seizures.

"This new drug is one of 15 new Faulding Inc. drugs on file for FDA approval and is the fourth FDA approval received by Faulding Inc. so far this calendar year. Purepac Pharmaceutical Co. received approval to market diclofenac delayed-release tablets, diflunisal tablets and indapamide tablets earlier this year. In addition, Purepac has commenced contract manufacturing of KADIAN(TM), a modified release morphine product, which is being marketed by Zeneca Inc.," said Moldin.

Purepac's 0.5 mg, 1mg, and 2mg clonazepam tablets are the generic equivalent of Klonopin(R). Total brand and generic revenues in 1995 were approximately $260 million. Product is expected to be available for shipment to customers first quarter, 1997.

Faulding Inc. develops, manufactures and markets human pharmaceuticals and medical devices. Faulding Inc. is the former Purepac Inc., which changed its name following its recent expansion beyond oral dosage forms into injectable drugs and drug delivery devices. The shares of Faulding Inc. are traded on NASDAQ under the symbol "FAUL." -0-

Note: Klonopin(R) is a registered trademark of Roche Laboratories.

CONTACT: Faulding Inc., Elizabeth

Lee Craker, 908/527-9100